Science 37 Adds New Head of Quality, Irena Lambridis
April 18 2023 - 7:59AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
Metasite™, today announced the appointment of Irena Lambridis as
its Global Head of Quality Assurance & Compliance. Irena will
be responsible for overseeing quality and compliance across all
functions, including the Company's newly announced global Centers
of Excellence in India, Pakistan, and Slovakia. This key
appointment reflects Science 37's commitment to quality as it
expands operations globally.
Irena brings nearly two decades of experience in clinical
research quality assurance, having held senior leadership positions
at KCR and Novella Clinical (now IQVIA Biotech). With her extensive
knowledge of good clinical practices (GCP), GXP, and computer
systems validation, she and her team will provide full quality and
compliance oversight for the company.
"We are thrilled to welcome Irena to our senior leadership
team," said David Coman, CEO of Science 37. "Her expertise in
protocol complexity, sponsor complexity including CROs,
organizational complexity and scale, globalization, and all
disciplines of quality and compliance will ensure that Science 37
is positioned as the undisputed leader of quality in our industry.
We look forward to her making an immediate impact."
"I am excited to join Science 37's experienced, patient-focused
team and help bring new therapies to market faster," said
Lambridis. "As virtual clinical trials become increasingly
important, I am eager to use my expertise to ensure the highest
quality of data and compliance at all times."
In her new role, Irena will play a vital part in Science 37's
mission to accelerate clinical research by enabling universal trial
access for patients through virtual clinical trials. Her
appointment reflects the company's ongoing commitment to excellence
and will be key to driving greater efficiency, speed, and scale as
Science 37 expands its global reach.
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to accelerate clinical research by enabling universal
trial access for patients. Through our Metasite™ we reach an
expanded population beyond the traditional site, delivering on our
goal of clinical research that works for everyone—with greater
patient diversity. Patients gain the flexibility to participate
from the comfort of their own homes, at their local community
provider, or at a traditional site when needed. Our Metasite is
powered by a proprietary technology platform with in-house medical
and operational experts that drive uniform study orchestration,
enabling greater compliance and high-quality data. To learn more,
visit www.science37.com, or email science37@science37.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the products offered by Science 37 and the
markets in which it operates, and Science 37’s anticipated growth
and profitability. These forward-looking statements generally are
identified by the words “believe,” “can,” “could”, “seek”,
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022 filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023 and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience 37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024